Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D0L6RF
|
|||
Former ID |
DIB010484
|
|||
Drug Name |
BAY1179470
|
|||
Indication | Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C76-C80; ICD-9: 140-229] | Phase 1 | [1] | |
Company |
Bayer healthcare pharmaceuticals
|
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | Fibroblast growth factor receptor 2 (FGFR2) | Target Info | Antagonist | [2] |
KEGG Pathway | MAPK signaling pathway | |||
Ras signaling pathway | ||||
Rap1 signaling pathway | ||||
Endocytosis | ||||
PI3K-Akt signaling pathway | ||||
Signaling pathways regulating pluripotency of stem cells | ||||
Regulation of actin cytoskeleton | ||||
Pathways in cancer | ||||
Prostate cancer | ||||
Central carbon metabolism in cancer | ||||
NetPath Pathway | IL1 Signaling Pathway | |||
Panther Pathway | FGF signaling pathway | |||
Pathway Interaction Database | FGF signaling pathway | |||
Reactome | Activated point mutants of FGFR2 | |||
WikiPathways | Regulation of Actin Cytoskeleton | |||
Ectoderm Differentiation | ||||
Hair Follicle Development: Organogenesis (Part 2 of 3) | ||||
Hair Follicle Development: Induction (Part 1 of 3) | ||||
Cardiac Hypertrophic Response | ||||
Signaling Pathways in Glioblastoma | ||||
Neural Crest Differentiation | ||||
Signaling by FGFR | ||||
MicroRNAs in cardiomyocyte hypertrophy | ||||
Angiogenesis |
References | Top | |||
---|---|---|---|---|
REF 1 | ClinicalTrials.gov (NCT01881217) First-in-man Dose Escalation Study of BAY1179470 in Patients With Advanced, Refractory Solid Tumors. U.S. National Institutes of Health. | |||
REF 2 | National Cancer Institute Drug Dictionary (drug id 751593). |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.